Physician profile
Stuart D Smith
NPI 1659375525
$2,421.66
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $693 · 2020: $525 · 2021: $976 · 2022: $228.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $344.47 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $245.79 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $240.29 | 2019-2021 | |
| Lilly USA, LLC | $181.98 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.93 | 2019-2021 | |
| Novo Nordisk INC | $162.52 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $151.50 | 2019-2022 | |
| Amgen INC. | $102.65 | 2019-2022 | |
| Abbvie INC. | $102.64 | 2021-2022 | |
| Amarin Pharma, INC. | $87.36 | 2020-2021 | |
| Collegium Pharmaceutical, INC. | $83.21 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.52 | 2019-2021 | |
| Astellas Pharma US INC | $73.71 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $50.63 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $43.78 | 2019-2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.64 | 2019-2021 | |
| Mylan Specialty L.P. | $41.07 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $34.77 | 2019-2020 | |
| Eisai INC. | $31.67 | 2021 | |
| Arbor Pharmaceuticals, INC. | $26.82 | 2019 | |
| Abbott Laboratories | $25.38 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $19.96 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $18.38 | 2019 | |
| Allergan, INC. | $15.78 | 2019 | |
| Dexcom, INC. | $14.94 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.87 | 2021 | |
| Sun Pharmaceutical Industries INC. | $11.40 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stuart Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.